1. Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil.
- Author
-
Campbell L, Barbini B, Cromarty B, Hamzah L, Williams D, Winston A, and Post FA
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Tenofovir adverse effects, Tenofovir therapeutic use, Tenofovir analogs & derivatives, Alanine adverse effects, Alanine therapeutic use, Anti-HIV Agents adverse effects, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, HIV Infections complications, Adenine analogs & derivatives, Adenine adverse effects, Adenine therapeutic use, Fanconi Syndrome chemically induced
- Abstract
Twenty-eight individuals who experienced proximal renal tubulopathy (PRT, Fanconi syndrome) while receiving tenofovir disoproxil initiated tenofovir alafenamide (TAF) and were followed for 5 years. None developed recurrent PRT or experienced significant changes in estimated glomerular filtration rate (by creatinine or cystatin-C), albuminuria, proteinuria, retinol-binding proteinuria, fractional excretion of phosphate, alkaline phosphatase, or bone mineral density at the lumbar spine. These data suggest that TAF is a well tolerated treatment option for individuals vulnerable to developing PRT., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF